MHUA vs. SURG, POCI, IRIX, DRIO, XAIR, PTHL, CODX, BSGM, FEMY, and NXGL
Should you be buying Meihua International Medical Technologies stock or one of its competitors? The main competitors of Meihua International Medical Technologies include SurgePays (SURG), Precision Optics (POCI), IRIDEX (IRIX), DarioHealth (DRIO), Beyond Air (XAIR), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), Co-Diagnostics (CODX), BioSig Technologies (BSGM), Femasys (FEMY), and NEXGEL (NXGL). These companies are all part of the "medical equipment" industry.
Meihua International Medical Technologies vs.
Meihua International Medical Technologies (NASDAQ:MHUA) and SurgePays (NASDAQ:SURG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, community ranking, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.
SurgePays has a consensus price target of $8.50, indicating a potential upside of 459.21%. Given SurgePays' stronger consensus rating and higher probable upside, analysts plainly believe SurgePays is more favorable than Meihua International Medical Technologies.
Meihua International Medical Technologies has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, SurgePays has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.
SurgePays received 170 more outperform votes than Meihua International Medical Technologies when rated by MarketBeat users.
In the previous week, SurgePays had 1 more articles in the media than Meihua International Medical Technologies. MarketBeat recorded 1 mentions for SurgePays and 0 mentions for Meihua International Medical Technologies. Meihua International Medical Technologies' average media sentiment score of 0.00 equaled SurgePays'average media sentiment score.
1.2% of Meihua International Medical Technologies shares are held by institutional investors. Comparatively, 6.9% of SurgePays shares are held by institutional investors. 66.6% of Meihua International Medical Technologies shares are held by company insiders. Comparatively, 29.4% of SurgePays shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Meihua International Medical Technologies has a net margin of 0.00% compared to SurgePays' net margin of -27.39%. Meihua International Medical Technologies' return on equity of 0.00% beat SurgePays' return on equity.
SurgePays has higher revenue and earnings than Meihua International Medical Technologies.
Summary
SurgePays beats Meihua International Medical Technologies on 10 of the 14 factors compared between the two stocks.
Get Meihua International Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for MHUA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Meihua International Medical Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:MHUA) was last updated on 1/21/2025 by MarketBeat.com Staff
Free MHUA Stock Alerts